Transitioning to Bundled Payments

Taking a more strategic approach to payer relationships may be the key to surviving new reimbursements models.
Published Online: June 25, 2014

As the healthcare industry moves away from fee-for-service reimbursements toward a bundled payment model that holds providers financially accountable for an entire episode of care, hospitals and health systems need strategies for maintaining cash flow and economic viability during the transition.

Despite the urgent need to adapt to the new reimbursement environment, healthcare organizations do not appear to be rethinking their payer relationships in large numbers. In the HealthLeaders Media Industry Survey 2014: Forging Healthcare's New Financial Foundation, while 39% of respondents cite reimbursement as being among the top three areas where their organization must improve in order to reach their financial targets within the next three years, only 25% include forming strategic partnerships with payers in the top three.

Read the full story here: http://bit.ly/1v5Un03

Source: Health Leaders Media



Feature
Recommended Articles
Cardiovascular disease may be the leading cause of death in the United States, but half of those deaths can be prevented, according to researchers from Emory’s Rollins School of Public Health.
New delivery models related to the recent healthcare reform legislation may help drive up utilization, as discussed by Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, in this seventh segment of the Healthcare Reform Stakeholders Summit, Spring 2015 series. They theorize that healthcare convenience and availability may actually lead to a loss in coordination of care.
With a growing understanding of the risk of cardiotoxicity associated with cancer treatment, cardio-oncology has emerged as an important subspecialty, resulting in the establishment of cardio-oncology programs most often based at or in collaboration with comprehensive cancer centers.
In this seventh segment of the Healthcare Reform Stakeholders Summit, Spring 2015 series, Francois de Brantes, MS, MBA, and Arthur Vercillo, MD, FACS, discussed a number of issues related to pricing transparency, including access to information, decreased pricing variability, and antitrust concerns.
During this one-on-one interview, a part of the Oncology Stakeholders Summit, Spring 2015 series, Michael Kolodziej, MD, discusses payer considerations regarding coverage for new cancer treatments such as immuno-oncology therapies.